Experimental combo targets tough cancers in early trial

NCT ID NCT05954871

Completed Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested an experimental drug called GDC-1971 combined with either osimertinib (for lung cancer) or cetuximab (for colorectal cancer) in 10 people with advanced cancers that had spread. The main goal was to check safety and find the right dose. Researchers also looked at how the drug moves through the body and whether tumors shrank.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GDC-1971 (an experimental drug) combined with either osimertinib or cetuximab
What this could lead to: If successful, this could point toward a new treatment option for people with advanced lung or colorectal cancer who have not responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 10 participants, focused on safety and dosing. It is not designed to prove effectiveness, and many early-stage drugs do not advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
Border Medical Oncology

Wodonga, New South Wales, 3690, Australia
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
START South Texas Accelerated Research Therapeutics-San Antonio

San Antonio, Texas, 78229, United States
Seoul National University Hospital

Seoul, 03080, South Korea
St Vincent's Hospital Melbourne

Fitzroy, Victoria, 3065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.